文献速递神经头颈MR

新型MRI对比剂钆匹醇对脑转移瘤患者放疗决策的影响

Impact of the Novel MRI Contrast Agent Gadopiclenol on Radiotherapy Decision Making in Patients With Brain Metastases.
PubMed 文献 · Invest Radiol · 2024-08-20

这项双盲交叉IIb期比较研究事后分析纳入13例脑转移瘤患者,比较钆匹醇与钆贝葡胺增强MRI对全脑放疗与立体定向放射外科决策的影响。钆匹醇在7例(54%)患者中显示额外转移灶,2例(15%)治疗决策改变;两种对比剂的平均GTV和脑V12无显著差异(P=0.694、P=0.974)。作者认为钆匹醇增强MRI改善脑转移瘤检出和表征,直接影响放疗决策,但需更大样本前瞻性评估确认。

要点

  • 钆匹醇较钆贝葡胺在7例(54%)患者中显示额外脑转移灶。
  • 两种对比剂间治疗决策改变2例(15%):1例从无治疗改为SRS,1例从SRS改为WBRT。
  • 读者评价钆匹醇靶体积定义改善63.9%(23/36),钆贝葡胺为22.2%(8/36)。

核心结论

  • 钆匹醇增强MRI改善脑转移瘤检出和表征,对WBRT与SRS之间的放疗决策有直接影响,并可进行更精确的靶区勾画和计划。

研究设计与样本

  • 双盲交叉IIb期比较研究的事后分析,纳入单一中心使用相同MRI扫描仪和协议的13例成年脑转移瘤患者,两种对比剂均按0.1 mmol/kg给药。

关键影像表现/征象

  • 钆匹醇较钆贝葡胺在7例(54%)患者中显示额外脑转移灶;63个转移灶中48个(24对)在两个MRI集均可见且GTV相等,13个GTV仅见于钆匹醇集(均值±SD 0.16±0.37 cm³),2个GTV仅见于钆贝葡胺集(均值±SD 0.01±0.01 cm³)。

诊断标准与关键数值

  • 根据转移灶数量决定SRS或WBRT;两种对比剂平均GTV和脑V12相当(P=0.694、P=0.974);平均Dice相似系数0.70±0.14(ρ=0.82);读者评价靶体积定义改善钆匹醇63.9%(23/36)vs钆贝葡胺22.2%(8/36),等效13.9%(5/36)。

临床应用与阅片要点

  • 作者认为钆匹醇增强MRI可改善脑转移瘤检出和表征,并对WBRT与SRS决策及靶区勾画有直接影响;原文结论指出需更大样本前瞻性评估确认这些发现。

局限性

  • 事后分析仅纳入单一中心使用相同MRI扫描仪和协议的数据。
  • 样本量为13例成年患者。
  • 原文结论指出需更大样本前瞻性评估确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The aim of this study was to assess the effect of gadopiclenol versus gadobenate dimeglumine contrast-enhanced magnetic resonance imaging (MRI) on decision-making between whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) for treatment of brain metastases (BMs).

METHODS: Patients with BMs underwent 2 separate MRI examinations in a double-blind crossover phase IIb comparative study between the MRI contrast agents gadopiclenol and gadobenate dimeglumine, both administered at 0.1 mmol/kg. The imaging data of a single site using identical MRI scanners and protocols were included in this post hoc analysis. Patients with 1 or more BMs in any of both MRIs were subjected to target volume delineation for treatment planning. Two radiation oncologists contoured all visible lesions and decided upon SRS or WBRT, according to the number of metastases. For each patient, SRS or WBRT treatment plans were calculated for both MRIs, considering the gross target volume (GTV) as the contrast-enhancing aspects of the tumor. Mean GTVs and volume of healthy brain exposed to 12 Gy (V 12 ), as well as Dice similarity coefficient scores, were obtained. The Spearman rank (ρ) correlation was additionally calculated for assessing linear differences. Three different expert radiation oncologists blindly rated the contrast enhancement for contouring purposes.

RESULTS: Thirteen adult patients were included. Gadopiclenol depicted additional BM as compared with gadobenate dimeglumine in 7 patients (54%). Of a total of 63 identified metastatic lesions in both MRI sets, 3 subgroups could be defined: A, 48 (24 pairs) detected equal GTVs visible in both modalities; B, 13 GTVs only visible in the gadopiclenol set (mean ± SD, 0.16 ± 0.37 cm 3 ); and C, 2 GTVs only visible in the gadobenate dimeglumine set (mean ± SD, 0.01 ± 0.01). Treatment indication was changed for 2 (15%) patients, 1 from no treatment to SRS and for 1 from SRS to WBRT. The mean GTVs and brain V 12 were comparable between both agents ( P = 0.694, P = 0.974). The mean Dice similarity coefficient was 0.70 ± 0.14 (ρ = 0.82). According to the readers, target volume definition was improved in 63.9% of cases (23 of 36 evaluations) with gadopiclenol and 22.2% with gadobenate dimeglumine (8 of 36), whereas equivalence was obtained in 13.9% (5 of 36).

CONCLUSIONS: Gadopiclenol-enhanced MRI improved BM detection and characterization, with a direct impact on radiotherapy treatment decision between WBRT and SRS. Additionally, a more exact target delineation and planning could be performed with gadopiclenol. A prospective evaluation in a larger cohort of patients is required to confirm these findings.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Sarria GR, Fleckenstein J, Eckl M, et al. Impact of the Novel MRI Contrast Agent Gadopiclenol on Radiotherapy Decision Making in Patients With Brain Metastases. Invest Radiol. 2024. PMID: 39159365. doi:10.1097/RLI.0000000000001115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。